$184.92 Million in Sales Expected for Seattle Genetics, Inc. (SGEN) This Quarter

Analysts expect Seattle Genetics, Inc. (NASDAQ:SGEN) to announce $184.92 million in sales for the current fiscal quarter, according to Zacks Investment Research. Five analysts have provided estimates for Seattle Genetics’ earnings, with estimates ranging from $179.03 million to $192.02 million. Seattle Genetics reported sales of $140.59 million during the same quarter last year, which indicates a positive year over year growth rate of 31.5%. The firm is scheduled to issue its next quarterly earnings results on Thursday, April 25th.

According to Zacks, analysts expect that Seattle Genetics will report full-year sales of $818.83 million for the current financial year, with estimates ranging from $816.00 million to $822.12 million. For the next fiscal year, analysts forecast that the business will report sales of $1.03 billion, with estimates ranging from $944.00 million to $1.11 billion. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research firms that follow Seattle Genetics.

Seattle Genetics (NASDAQ:SGEN) last posted its quarterly earnings results on Thursday, February 7th. The biotechnology company reported ($0.75) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.39) by ($0.36). The company had revenue of $174.50 million for the quarter, compared to analyst estimates of $164.03 million. Seattle Genetics had a negative return on equity of 19.33% and a negative net margin of 34.01%. The business’s revenue for the quarter was up 34.6% compared to the same quarter last year. During the same period last year, the company earned ($0.41) earnings per share.

A number of equities research analysts have issued reports on the company. BidaskClub upgraded Seattle Genetics from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, February 20th. HC Wainwright reissued a “buy” rating and set a $98.00 price target on shares of Seattle Genetics in a report on Friday, February 8th. Piper Jaffray Companies lowered their price target on Seattle Genetics to $64.00 and set a “neutral” rating on the stock in a report on Thursday, February 7th. TheStreet raised Seattle Genetics from a “d+” rating to a “c” rating in a report on Friday, February 1st. Finally, Zacks Investment Research raised Seattle Genetics from a “hold” rating to a “buy” rating and set a $82.00 price target on the stock in a report on Wednesday, January 30th. One analyst has rated the stock with a sell rating, three have assigned a hold rating, ten have assigned a buy rating and two have given a strong buy rating to the stock. Seattle Genetics has a consensus rating of “Buy” and a consensus price target of $80.82.

NASDAQ:SGEN traded up $1.02 during trading hours on Friday, hitting $74.62. The stock had a trading volume of 994,987 shares, compared to its average volume of 833,364. The company has a market capitalization of $11.82 billion, a price-to-earnings ratio of -45.22 and a beta of 2.32. Seattle Genetics has a 1-year low of $47.75 and a 1-year high of $84.37.

In related news, CFO Todd E. Simpson sold 10,000 shares of Seattle Genetics stock in a transaction dated Monday, March 4th. The stock was sold at an average price of $75.00, for a total transaction of $750,000.00. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Vaughn B. Himes sold 8,000 shares of Seattle Genetics stock in a transaction dated Friday, March 8th. The stock was sold at an average price of $68.72, for a total value of $549,760.00. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 83,444 shares of company stock worth $5,656,373. 33.80% of the stock is owned by corporate insiders.

A number of institutional investors and hedge funds have recently modified their holdings of the stock. American Century Companies Inc. purchased a new position in Seattle Genetics in the 4th quarter worth about $44,729,000. Geode Capital Management LLC increased its stake in Seattle Genetics by 6.6% in the 4th quarter. Geode Capital Management LLC now owns 1,116,057 shares of the biotechnology company’s stock worth $63,196,000 after purchasing an additional 69,251 shares in the last quarter. Norges Bank purchased a new position in Seattle Genetics in the 4th quarter worth about $44,082,000. Teacher Retirement System of Texas increased its stake in Seattle Genetics by 22.2% in the 4th quarter. Teacher Retirement System of Texas now owns 15,940 shares of the biotechnology company’s stock worth $903,000 after purchasing an additional 2,898 shares in the last quarter. Finally, CWM Advisors LLC purchased a new position in Seattle Genetics in the 4th quarter worth about $265,000.

About Seattle Genetics

Seattle Genetics, Inc, a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company markets ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas.

Recommended Story: What is Call Option Volume?

Get a free copy of the Zacks research report on Seattle Genetics (SGEN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Seattle Genetics (NASDAQ:SGEN)

Receive News & Ratings for Seattle Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seattle Genetics and related companies with MarketBeat.com's FREE daily email newsletter.